Nail-Biting Time for Trials of COX-2 Drugs

Author:

JCJennifer Couzin
Jennifer Couzin

3 December 2004

journal article
other
Published by American Association for the Advancement of Science (AAAS) in Science

Vol. 306 (5702) , 1673-1675
DOI:10.1126/science.306.5702.1673
PMID:15576585

Abstract

Preliminary studies suggest that the COX-2 inhibitor Celebrex may stem cancer and Alzheimer9s disease, but testing these possibilities has just gotten tougher.

Keywords

DRUGS PRELIMINARY
NAIL-BITING TIME
INHIBITOR CELEBREX
PRELIMINARY STUDIES
STUDIES SUGGEST
STEM CANCER
DISEASE
DRUGS
TIME
TRIALS